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Schroder: CRISPR and the Obviousness Standard

CRISPR HAS ALREADY REVOLUTIONIZED GENETICS, WHY
NOT THE OBVIOUSNESS STANDARD TOO?
Kris Schroder

I. INTRODUCTION

Throughout history humanity has transformed and adapted to the
world’s various climates.1 One of the methods humanity has
employed to adapt to the world is known as artificial selection. 2 The
first farmers would choose the seeds of plants that produced the most
favorable traits, such as the plant with the most fruit, to plant in the
following season.3 Over many years, this selection process produced
domesticated plants that bore little resemblance to wild plants.4 As
human industry developed and science advanced concurrently,
favorable and unfavorable traits were found to be controlled by
genes.5 The biotechnology industry emerged as methods to
artificially select genes controlling these traits were discovered.6 The
methods, however, were tedious and expensive. In the last decade, a
new technology has emerged known as CRISPR-Cas9 (“CRISPR”).7
This new technology allows humanity to accelerate the artificial
selection process by editing the genome of organisms in a quicker
and less expensive way than previous technologies.8 The economic
benefit of this technology is enormous.9 In fact, market forecasts
estimate that by 2020, the Genome Editing market will be worth
1. Nathanael Massey, Humans May Be the Most Adaptive Species, SCIENTIFIC AMERICAN
(Sept. 25, 2013), https://www.scientificamerican.com/article/humans-may-be-most-adaptive-species/
[https://perma.cc/R9LH-TSXQ].
2. Andrea Becker, Describe the Process of Artificial Selection, SCIENCING (Apr. 25, 2017),
https://sciencing.com/describe-process-artificial-selection-16957.html [https://perma.cc/NB2Z-3YNX].
3. Gabriel Rangel, From Corgis to Corn: A Brief Look at the Long History of GMO
Technology,
HARVARD
SCIENCE
IN
THE
NEWS
BLOG
(Aug.
9,
2015),
http://sitn.hms.harvard.edu/flash/2015/from-corgis-to-corn-a-brief-look-at-the-long-history-of-gmotechnology/ [https://perma.cc/HU3X-E2GG].
4. Id.
5. JR Minkel, Gene Behind Mendel's Green Pea Seeds Finally Identified, SCIENTIFIC
AMERICAN (Jan. 5, 2007), https://www.scientificamerican.com/article/gene-behind-mendels-green/
[https://perma.cc/4C5Z-L9M8].
6. Gabriel Rangel, From Corgis to Corn: A Brief Look at the Long History of GMO
Technology,
HARVARD
SCIENCE
IN
THE
NEWS
BLOG
(Aug.
9,
2015),
http://sitn.hms.harvard.edu/flash/2015/from-corgis-to-corn-a-brief-look-at-the-long-history-of-gmotechnology/ [https://perma.cc/HU3X-E2GG].
7. Id.
8. Id.
9. See Genome Editing/Genome Engineering Market Worth 6.28 Billion USD by 2022,
MARKETSANDMARKETS,
http://www.marketsandmarkets.com/PressReleases/genome-editingengineering.asp [https://perma.cc/MMS2-WRC6].
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nearly $6.28 billion.10 CRISPR is already the most utilized tool in the
genome editing market.11 As Earth’s climate continues to change,
and the pace of that change escalates, humanity will need to continue
adapting—potentially at a much faster rate.12 Thus, the economic
value found in genome editing will likely continue to increase as
humanity continues to use it to adapt to the changing climate on the
planet.13
A legal dispute around two of the patents involving CRISPR has
been at the center of news for this technology.14 The first, put forth
by a team at the University of California, is directed to CRISPR-Cas9
systems not restricted to any environment.15 The second, put forth by
a team at the Broad Institute, is directed to CRISPR-Cas9 systems in
a specific cellular environment.16 The legal issue is whether the
second patent is rendered obvious by the first patent, and what
standard should be used to make that determination.
Part II of this note will talk about the legal background of the
obviousness standard, the background of the CRISPR technology,
and a brief discussion about the patents and cases in the CRISPR
dispute. Part III of this note will argue for a more flexible standard to
be adopted by the federal circuit, as well as suggesting new factors to
be considered. Part IV will conclude the argument.
II. BACKGROUND

When two patents potentially overlap with one another, the United
States Patent and Trademark Office must resolve any issues and
determine which patent gets priority.17 Prior to the adoption of the
America Invents Act in 2011 (“AIA”), this was done by 35 U.S.C. §
10. Id.
11. Id.
12. Juliet Eilperin, Brady Dennis and Chris Mooney, Trump administration sees a 7-degree rise
in global temperatures by 2100, THE WASHINGTON POST (Sept. 28, 2018),
https://www.washingtonpost.com/national/health-science/trump-administration-sees-a-7-degree-rise-inglobal-temperatures-by-2100/2018/09/27/b9c6fada-bb45-11e8-bdc090f81cc58c5d_story.html?noredirect=on&utm_term=.f51cd1eb0d71 (The world temperature is
estimated to increase seven degrees Fahrenheit by the end of the century.) [https://perma.cc/GS5WQT2T].
13. See Genome Editing/Genome Engineering Market Worth 6.28 Billion USD by 2022,
MARKETSANDMARKETS,
http://www.marketsandmarkets.com/PressReleases/genome-editingengineering.asp [https://perma.cc/MMS2-WRC6].
14. Jon Cohen, How the battle lines over CRISPR were drawn, SCIENCE (Feb. 15, 2017),
https://www.sciencemag.org/news/2017/02/how-battle-lines-over-crispr-were-drawn
[https://perma.cc/396J-ZBHM].
15. U.S. Patent App. No. 20140068797 (filed Mar. 15, 2013).
16. U.S. Patent No. 8,697,359 (filed Oct. 13, 2013).
17. 35 U.S.C. § 102.
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102(g) interference proceedings.18 After the AIA changes came into
effect, the issues are resolved through two mechanisms known as
Inter Partes Review19 and Post Grant Review.20 The pre-AIA statute
for 35 U.S.C § 102(g) will apply in this case because the AIA
changes went into effect in waves and do not apply to these patents in
the determination of priority.21 In Section A, the nonobvious
requirement for obtaining a patent will be analyzed—diving into the
Graham analysis and the obvious-to-try standard. Section B will look
at the standard of review for obviousness determination and the
reasonable expectation standard. Section C will explain the biology
and importance of the CRISPR/Cas9 technology and the competing
patents. Section D will give a brief overview of the Patent Trial and
Appeal Board’s decision and reasoning in The Broad Institute, Inc. v.
The Regents of the University of California. Section E will give an
overview of the Federal Circuit’s reasoning and decision in Regents
of the University of California v. Broad Institute, Inc.
A. The Nonobvious Requirement of Patentability

The United States Constitution gives Congress the power to enact
laws concerning patents.22 The primary requirements of a patentable
invention are utility,23 novelty,24 and nonobviousness.25 To satisfy the
utility requirement, a patent must show that it is useful. 26 An
invention fails the novelty requirement, or is “anticipated,” when
each claim of the patent is described in a single prior art reference.27
18. 35 U.S.C.S. § 102(g) (LexisNexis 2010).
19. 35 U.S.C. § 311.
20. 35 U.S.C. § 321.
21. See The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048
(P.T.A.B. 2017).
22. U.S. CONST. art. I, § 8, cl. 8 grants Congress the power to “promote the Progress of Science
and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their
respective Writings and Discoveries.”
23. 35 U.S.C. § 101 requires that the invention be a new and useful process, machine,
manufacture, or composition of matter.
24. 35 U.S.C. § 102 requires that the invention be novel and sets out various exceptions to prior
art and bars to patentability.
25. 35 U.S.C. § 103 states that a patent may not be obtained if the differences between the
claimed invention and the prior art are such that the claimed invention as a whole would have been
obvious before the effective filing date of the claimed invention to a person having ordinary skill in the
art to which the claimed invention pertains.
26. See Brenner v. Manson, 383 U.S. 519, 535 (1966). One can fail the utility requirement when
it is not apparent why the invention is useful or if the utility is not credible.
27. See Verdegaal Bros. v. Union Oil Co., 814 F.2d 628, 631 (Fed. Cir. 1987). Examples of prior
art under the Pre-AIA include, but are not limited to, printed publications, patents, and patent
applications. 35 U.S.C. § 102.
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The nonobvious requirement can trace its origins in the United States
in the 1851 Supreme Court case Hotchkiss v. Greenwood.28 The
requirement was then codified in the Patent Act of 1952.29 The
Supreme Court tackled the language of the newly codified
nonobviousness requirement in the pinnacle case Graham v. John
Deere Co. of Kansas City.30 The Court held that under 35 U.S.C. §
103, “the prior art’s scope and content should be determined, the
differences between the prior art and the claims should be identified,
and the level of ordinary skill in the art should resolved.”31
Additionally, secondary considerations should be relevant as indicia
of obviousness or nonobviousness.32 The Graham Court listed
commercial success, long-felt need, and failure of others as examples
of these secondary considerations.33 The Graham Court then cited a
law review note that listed additional factors such as commercial
acquiescence, simultaneous solution, professional approval, and
progress through the Patent Office.34 Other secondary factors
weighed by the Graham Court include: copying by others in the field,
respect by the industry, acclaim, unexpected results, skepticism,
teaching away, long experimentation, and utility. 35 The Court of
Appeals for the Federal Circuit, in an effort to apply the Graham
analysis, used an approach known as the “teaching, suggestion, or
motivation" test (“TSM test”).36 In the TSM test, a patent claim is
obvious only if "some motivation or suggestion to combine the prior
art teachings" can be found in the prior art, the nature of the problem,
or the knowledge of a person having ordinary skill in the art.37 The
Supreme Court, in KSR Int’l Co. v. Teleflex Inc., overturned the TSM
test.38 They reasoned that “when a court transforms the general
principle into a rigid rule that limits the obviousness inquiry . . . it
28. Hotchkiss v. Greenwood, 52 U.S. 248, 267 (1851) (More ingenuity and skill needed than
possessed by an ordinary mechanic, otherwise the invention is just the work of the skillful mechanic, not
of an inventor.).
29. 35 U.S.C. § 103 (1952).
30. Graham v. John Deere Co., 383 U.S. 1 (1966).
31. Id. at 17.
32. Id. at 18.
33. Id. at 17.
34. Jonathan J. Darrow, Secondary Considerations: A Structured Framework for Patent
Analysis, 74 Alb. L. Rev. 47, 50 (2010) (citing Richard L. Robbins, Note, Subtests of
"Nonobviousness”: A Nontechnical Approach to Patent Validity, 112 U. PA. L. REV. 1169 (1964)).
35. Jonathan J. Darrow, Secondary Considerations: A Structured Framework for Patent
Analysis, 74 Alb. L. Rev. 47, 51 (2010).
36. KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 407 (2007); see ACS Hosp. Sys. v. Montefiore
Hosp., 732 F.2d 1572, 1577 (Fed. Cir. 1984).
37. Id.
38. KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 407 (2007).
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errs.”39 The KSR Court also stated that the fact a combination was
obvious to try, when considering market pressure and the finite
number of identified, predictable solutions, may be enough to show
obviousness under 35 U.S.C. § 103.40 The KSR Court reasoned that
granting protection to advances that occur without real innovation
slows progress and may deprive previous patents of their value.41
By overturning the TSM test and commenting on the validity of an
obvious-to-try standard, the court in KSR effectively increased the
relevance of secondary consideration and simultaneously criticized
the static approaches by the Federal Circuit.42 These secondary
considerations may be particularly useful when expert opinions are
contradictory due to the complicated nature of the invention.43
Subsequent cases have seen the Federal Circuit interpret the KSR
standard.44 In Abbot Labs v. Sandoz Inc., the court reasoned that
KSR’s obvious-to-try standard should be considered in the particular
context of the case. Elements of each case must be analyzed,
including the characteristics of the technology, the advanced nature
of the science, the specificity of the prior art, and the predictability of
results in the technological field of interest.45 Indeed, every case
involving a question of nonobviousness should be decided upon its
own facts.46 The Federal Circuit also refused to limit the KSR holding
to predictable arts, opting to include less predictable arts such as
biotechnology.47 However, when prior art steers a person having
ordinary skill in the art away from a prior art reference, the invention
cannot be deemed “obvious to try.”48 The court in Pharmastem
Therapeutics, Inc. v. Viacell, Inc. reasoned that scientific
confirmation may be a valuable contribution, but it does not make an
invention patentable.49
The obvious-to-try standard mentioned in KSR seems to be utilized
when a court cannot find sufficient evidence of secondary
considerations and determines nonobviousness based only on the
reasoning that the invention would have been obvious for a person
39. Id. at 419.
40. Id. at 421.
41. Id. at 419.
42. Jonathan J. Darrow, Secondary Considerations: A Structured Framework for Patent
Analysis, 74 Alb. L. Rev. 47, 54 (2010).
43. Id. at 67.
44. See Abbott Labs. v. Sandoz, Inc., 544 F.3d 1341 (Fed. Cir. 2008).
45. Id. at 1352.
46. In re Jones, 958 F.2d 347, 350 (Fed. Cir. 1992).
47. In re Kubin, 561 F.3d 1351, 1360 (Fed. Cir. 2009).
48. Takeda Chem. Indus. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1359 (Fed. Cir. 2007).
49. 491 F.3d 1342, 1363-64 (Fed. Cir. 2007).
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having ordinary skill in the art to try and make.50 The obvious-to-try
standard was originally employed prior to the adoption of the
statutory nonobviousness standard.51 However, prior to KSR, the
Federal Circuit rejected the obvious-to-try standard in In re
O’Farrell.52 The O’Farrell court clarifies that courts generally
misapply the standard.53 One such misapplication is when “what was
‘obvious to try’ was to explore a new technology or general approach
that seemed to be a promising field of experimentation, where the
prior art gave only general guidance as to the particular form of the
claimed invention or how to achieve it.”54 The O’Farrell court
eventually held that “[f]or obviousness under § 103, all that is
required is a reasonable expectation of success.”55 Post-KSR, the
Federal Circuit has begun to side step the obvious-to-try standard by
using the reasonable expectation standard.56 An issue arises in
scientific research, where the inherent unpredictable nature of the
research clouds the correct application of the reasonable expectation
of success standard.57 The standard is problematic because there is
not a test to determine what degree of expectation of success is
“reasonable.”58 Confusion has resulted as courts utilize the standard
in an effort to ignore the importance of inherent unpredictability.59
To satisfy the reasonable expectation of success standard, an
inventor must do more than just vary all parameters until one avenue
results in success when the prior art gave no indication of either the
critical parameters or the direction as to which one of the parameters
is likely to be successful.60 Reasonable expectation of success cannot
be fulfilled by an opinion that success is inherent.61 Additionally,
when an inventor proceeds in opposition to accepted wisdom in their

50. Andrew V. Trask, Obvious to Try: A Proper Patentability Standard in the Pharmaceutical
Arts, 76 Fordham L. Rev. 2625, 2634 (2008).
51. See In re Kepler, 30 C.C.P.A. 726, 730 (U.S. C.C.P.A. 1942) (A patent should not be granted
for [the] discovery of a result that would flow naturally from the teachings of the prior art.).
52. In re O'Farrell, 853 F.2d 894, 903 (Fed. Cir. 1988).
53. Id.
54. Id.
55. Id. at 905.
56. Andrew V. Trask, Obvious to Try: A Proper Patentability Standard in the Pharmaceutical
Arts, 76 Fordham L. Rev. 2625, 2654 (2008); see Pharmastem Therapeutics, Inc. v. Viacell, Inc., 491
F.3d 1342 (Fed. Cir. 2007); see Aventis Pharma Deutschland GmbH v. Lupin, Ltd., 499 F.3d 1293 (Fed.
Cir. 2007).
57. Kathleen N. McKereghan, The Nonobviousness of Inventions: In Search of a Functional
Standard, 66 WASH. L. REV. 1061, 1072 (1991).
58. Id. at 1076.
59. Id.
60. Medichem, S.A. v. Rolabo, S.L., 437 F.3d 1157, 1165 (Fed. Cir. 2006).
61. In re Rinehart, 531 F.2d 1048, 1054 (C.C.P.A. 1976).
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field, that is evidence of nonobviousness.62 The Federal Circuit
considers reasonable expectation of success a question of fact. 63 The
reasonable expectation of success standard seems to have originated
from the 1961 Court of Customs and Patent Appeals64 case, In re
Moreton.65 The court in In re Moreton reasoned:
What this amounts to is an argument that if one slavishly
following the prior art, albeit with a little educated imagination,
will sometimes succeed and sometimes fail, then he is always
entitled to a patent in case of success. This is not the intention
behind 35 U.S.C. 103. Obviousness does not require absolute
predictability . . . the mere possibility of failure does not render
their successful use “unobvious.”66
Subsequent courts ignored the statement that “the mere possibility of
failure does not render their successful use ‘unobvious,’” and focused
instead on the idea that obviousness does not require absolute
predictability.67 Building on that, the court took this notion one step
further by holding that “an invention can be said to be obvious if one
ordinarily skilled in the art would consider that it was logical to
anticipate with a high degree of probability that a trial of it would be
successful.”68 A “high degree of probability” further evolved into “at
least some predictability is required.”69 Finally, the reasonable
expectation of success standard appeared in In re Rinehart.70

62. Charles v. Hedges, 783 F.2d 1038, 1041 (Fed. Cir. 1986).
63. Par Pharm., Inc. v. TWi Pharm., Inc., 773 F.3d 1186, 1196 (Fed. Cir. 2014).
64. The Court of Customs and Patent Appeals had jurisdiction over cases regarding appeals from
the Patent Office in patent and trademark cases from 1909-1982, upon which the Court of Customs and
Patent Appeals was merged with the Court of Claims to form the jurisdictional basis for the Federal
Circuit. See Federal Judicial Center, U.S. Court of Customs and Patent Appeals, 1929-1982, FEDERAL
JUDICIAL CENTER, https://www.fjc.gov/history/courts/u.s.-court-customs-and-patent-appeals-19291982 [https://perma.cc/HW75-DTXE]; Federal Judicial Center, Court of Claims, 1855-1982, FEDERAL
JUDICIAL
CENTER,
https://www.fjc.gov/history/courts/court-claims-1855-1982
[https://perma.cc/6VTD-8ELC]; Federal Judicial Center, Federal Judicial Circuits: Federal Circuit,
FEDERAL JUDICIAL CENTER, https://www.fjc.gov/history/administration/federal-judicial-circuitsfederal-circuit [https://perma.cc/DV5N-G7LF].
65. In re Moreton, 288 F.2d 940 (C.C.P.A. 1961).
66. Id. at 943-944.
67. In re Huellmantel, 324 F.2d 998, 1000 (C.C.P.A. 1963).
68. In re Pantzer, 341 F.2d 121 (C.C.P.A. 1965).
69. In re Naylor, 369 F.2d 765, 768 (C.C.P.A. 1966).
70. In re Rinehart, 531 F.2d 1048, 1054 (C.C.P.A. 1976).
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B. Standard of Review for Obviousness

Obviousness is a question of law based on underlying facts. 71 The
underlying factual findings include the Graham analysis as discussed
above.72 Objective considerations of obviousness are questions of
fact that should be reviewed for substantial evidence supporting the
findings.73 Relevant evidence such as secondary considerations
should not be disregarded when determining obviousness.74 For
example, the Federal Circuit in In Re Dow Chemical Co. stated that
the criteria for determination of obviousness is whether prior art
would suggest to a person having reasonable skill in the art that “this
process should be carried out and would have a reasonable likelihood
of success, viewed in light of the prior art.”75 Similarly, the Supreme
Court in Pfizer, Inc. v. Apotex, Inc. held that “obviousness cannot be
avoided simply by a showing of some degree of unpredictability in
the art so long as there was a reasonable probability of success.”76
Substantial weight may be given to evidence of the unexpected
nature of results in favor of nonobviousness.77 Furthermore, if the
evidence of a case supports several reasonable conclusions that
contradict each other, the USPTO’s decision will not be found as
unsupported by substantial evidence because they chose one
conclusion over another alternative conclusion.78 Patent laws should
not have limitations and conditions read into them which the
legislature has not expressed.79 When prior art discloses the general
conditions of a claim, one may not simply discover workable ranges
by routine experimentation and call it inventive.80
C. The CRISPR Technology.

Deoxyribonucleic acid (“DNA”), is the blueprint for life on this

71. WBIP, LLC v. Kohler Co., 829 F.3d 1317, 1326 (Fed. Cir. 2016).
72. Graham v. John Deere Co., 383 U.S. 1,17 (1966). See also Icon Health & Fitness, Inc. v.
Strava, Inc., 849 F.3d 1034, 1039 (Fed. Cir. 2017).
73. Arctic Cat Inc. v. Bombardier Rec. Prods., 876 F.3d 1350, 1358 (Fed. Cir. 2017).
74. Stratoflex, Inc. v. Aeroquip Corp., 713 F.2d 1530, 1538 (Fed. Cir. 1983) (The relevant
evidence on the obviousness-nonobviousness issue ... includes evidence on what has now been called
"secondary considerations." It is error to exclude that evidence from consideration.).
75. In re Dow Chem. Co., 837 F.2d 469, 473 (Fed. Cir. 1988).
76. Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348, 1364 (Fed. Cir. 2007).
77. Burlington Indus. v. Quigg, 822 F.2d 1581, 1584 (Fed. Cir. 1987).
78. In re Jolley, 308 F.3d 1317, 1320 (Fed. Cir. 2002).
79. Diamond v. Diehr, 450 U.S. 175, 182 (1981) (citing Diamond v. Chakrabarty, 447 U.S. 303,
308 (1980)).
80. In re Aller, 220 F.2d 454, 456 (C.C.P.A. 1955).
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planet.81 DNA is made up of two strands of chemical compounds
called nucleotides that bind one another in complementary pairs.82
This complementarity allows DNA to store an enormous amount of
information in the sequence of its nucleotides.83 Some of the
information organized in DNA are called genes.84 The entirety of an
organism’s DNA is referred to as a genome.85 An organism’s cell
transcribes genes in the form of messenger ribonucleic acid
(“mRNA”), and sends this “message” to machinery within the cell to
produce proteins from the initial blueprint.86 Proteins then carry out
the functions of the organism.87 When something is wrong with these
proteins, they may not function correctly—potentially leading to
disease.88
In many diseases, proteins function incorrectly due to errors in the
DNA “blueprint.”89 The symptoms of these diseases lead researchers
to study what protein is functioning incorrectly, and which gene
encodes that protein.90 These diseases can then be studied in cell lines
and animals if the expression of these genes are lowered or
eliminated.91 The ability to edit genes is an incredibly powerful tool
for both research and treatment of diseases.92
In the past few decades, tools have been developed to allow for
genome editing.93 The primary examples of these tools are zinc
finger nucleases (“ZFNs”) and TAL effector nucleases
(“TALENs”).94 ZFNs and TALENs use custom engineered proteins
to bind a specific sequence of DNA and cut the DNA in a specific
spot.95 Custom engineering these proteins is difficult and time

81. JAMES D. WATSON ET AL., MOLECULAR BIOLOGY OF THE GENE, 21, (Beth Wilbur et.
al. eds.), 7th ed., 2014.
82. Id. at 24.
83. Id. at 30.
84. Id. at 31.
85. Id. at 40.
86. Id. at 35-36.
87. DANIEL L. HARTL & MARYELLEN RUVOLO, GENETICS: ANALYSIS OF GENES AND
GENOMES, 14-15, (Ty Field et. al. eds.), 8th ed., 2012.
88. Id.
89. Id.
90. Id.
91. JAMES D. WATSON ET AL., MOLECULAR BIOLOGY OF THE GENE, 797, (Beth Wilbur et.
al. eds.), 7th ed., 2014.
92. Id. at 797-98; If a gene is edited such that it can’t be transcribed, then no protein can be
made. If no protein is made, then an organism may have symptoms similar to a disease.
93. Jennifer A. Doudna & Emmanuelle Charpentier, The new frontier of genome engineering
with CRISPR-Cas9, 346 SCIENCE 1077 (2014).
94. Id.
95. Id.
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consuming.96 The invention at issue in the patents controlled by the
University of California and the Broad Institute involves a new
technology, known as CRISPR-Cas9.97 CRISPR is composed of a
protein (Cas9) that cuts DNA, and a RNA that guides the protein to a
specific site in the genome.98
To put this in an analogy, imagine there is an attorney that travels a
lot for work. The attorney does not always go to the same place; in
fact, they travel all over the world. Unfortunately, the attorney cannot
fly, so they have to drive to all of their destinations. Suppose that the
destinations represent a location within an organism’s genome, and
the attorney’s car represents the ZFNs/TALENs or CRISPR. With
ZFNs and TALENs, every time the attorney wants to go someplace
new, they will have to build a new car because the directions to their
destination are built into the car. With CRISPR, the car stays the
same, all the attorney needs to do is download new directions.
Furthermore, while in the ZFN/TALEN car, the attorney can only go
to one destination; as opposed to the CRISPR car, where the attorney
can go to multiple destinations in the same trip by “downloading”
multiple sets of directions.
This analogy emphasizes both the flexibility and utility of the
CRISPR invention. The guide RNAs which guide the CRISPR
protein complex to a specific site in the genome cost around $100
USD to create, which is very cost efficient by scientific standards.99
The utility of CRISPR stretch across a wide range of industries, with
the two most important being biotechnology and medical research.100
Therefore, a patent that gives the right to use or license CRISPR is
valuable to hold.
1. The University of California Berkeley Discovery and Patent

On August 17, 2012, Jennifer Doudna and Emmanuelle

96. Id.
97. See The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048
(P.T.A.B. 2017); Regents of the University of California v. Broad Institute, Inc., 2018 U.S. App. LEXIS
25535 (Fed. Cir. 2018); U.S. Patent No. (filed Oct. 13, 2013); U.S. Patent App. No. 20140068797 (filed
Mar. 15, 2013).
98. Jennifer A. Doudna & Emmanuelle Charpentier, The new frontier of genome engineering
with CRISPR-Cas9, 346 SCIENCE 1077 (2014).
99. Annie Snead, Mail-Order CRISPR Kits Allow Absolutely Anyone to Hack DNA, SCIENTIFIC
AMERICAN Nov. 2, 2017, https://www.scientificamerican.com/article/mail-order-crispr-kits-allowabsolutely-anyone-to-hack-dna/ [https://perma.cc/BE33-CXNP].
100. Katrina Megget, Money from Genes: CRISPR Goes Commercial, SCIENTIFIC AMERICAN,
(Jan. 22, 2016), https://www.scientificamerican.com/article/money-from-genes-crispr-goes-commercial/
[https://perma.cc/4CH5-EFPK].
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Charpentier (collectively “the University of California’s team”)101
published their research paper in Science describing their use of the
CRISPR system.102 In the paper, they demonstrated the ability of
CRISPR to cleave double stranded DNA for the first time.103 They
concluded their paper with the following statement:
Zinc-finger nucleases and [TALEN]s have attracted
considerable interest as artificial enzymes engineered to
manipulate genomes. We propose an alternative methodology
based on RNA-programmed Cas9 that could offer considerable
potential for gene-targeting and genome-editing applications.104
Even though the paper does not show CRISPR activity in a cellular
environment, it does explicitly lay out the potential impact of the
technology on the genome-editing field.105
In the patent application 13/842,859, filed on March 15, 2013, the
relevant claim that the University of California’s team makes is
Claim 165, which states:
A method of cleaving a nucleic acid comprising contacting a
target DNA molecule having a target sequence with an
engineered and/or non-naturally-occurring Type II Clustered
Regularly Interspaced Short Palindromic Repeats (CRISPR)CRISPR association (Cas)(CRISPR-Cas) system comprising
a) A Cas9 protein; and
b) A single molecule DNA-targeting RNA comprising
i) A targeter-RNA that hybridizes with the target
sequence, and
ii) An activator-RNA that hybridizes with the targeterRNA to form a double-stranded RNA duplex of a
protein-binding segment,
wherein the activator-RNA and the targeter-RNA are
covalently linked to one another with intervening nucleotides,
wherein the single molecule DNA-targeting RNA forms a
complex with the Cas9 protein, whereby the single molecule
DNA-targeting RNA targets the target sequence, and the Cas9

101. Jennifer Doudna works for the University of California, Berkeley. Emmanuelle Charpentier
works for the University of Vienna, and collaborated with Doudna.
102. Jinek et al., A programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial
Immunity, 337 SCIENCE 816-821 (2012).
103. Id.
104. Id. at 820.
105. Id. at 816-21.
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protein cleaves the target DNA molecule.106
The University of California’s patent is not limited to any particular
environment.107 The Broad Institute makes the claim that this lack of
limitation distinguishes their patent from the patent held by the
University of California.
2. The Broad Institute’s Discovery and Patent

On February 15, 2013, Feng Zhang published his research paper in
Science demonstrating the use of the CRISPR system in mammalian
cell lines.108 This paper cited to the 2012 paper described supra by
Doudna and Charpentier.109 In the 8,697,359 patent, which was filed
October 15, 2013, the Broad Institute (who employees Zhang) made
the following claim:
A method of altering expression of at least one gene product
comprising introducing into a eukaryotic cell containing and
expressing a DNA molecule having a target sequence and
encoding the gene product an engineered, non-naturally
occurring Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPR)--CRISPR associated (Cas) (CRISPR-Cas)
system comprising one or more vectors comprising:
a) a first regulatory element operable in a eukaryotic cell
operably linked to at least one nucleotide sequence
encoding a CRISPR-Cas system guide RNA that
hybridizes with the target sequence, and
b) a second regulatory element operable in a eukaryotic
cell operably linked to a nucleotide sequence encoding a
Type-II Cas9 protein,
wherein components (a) and (b) are located on same or different
vectors of the system, whereby the guide RNA targets the target
sequence and the Cas9 protein cleaves the DNA molecule,
whereby expression of the at least one gene product is altered;
and, wherein the Cas9 protein and the guide RNA do not
naturally occur together. 110
106. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048
(P.T.A.B. 2017).
107. Id.
108. Cong et al., Multiplex Genome Engineering Using CRISPR/Cas Systems, 339 SCIENCE 81923 (2013).
109. Id.
110. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048
(P.T.A.B. 2017).
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It should be noted that this patent was granted an accelerated
examination.111 In essence, the difference between this patent and
University of California’s application was that Broad Institute’s
claims were limited to the method being used in eukaryotic cells.112
Regardless, the Broad Institute has attempted to create a licensing
pool for the CRISPR technology, which combines other patents so
that costs can be reduced and scientists may benefit.113
D. PTAB Decision

The battle over CRISPR has occurred in courts and among the
researcher’s scientific peers.114 Major awards in the life sciences have
been given to both parties for their work on CRISPR.115 The
University of California suggested the interference proceeding to
determine if there was overlap between the two patents. 116 When
patentably indistinct subject matter gives rise to a dispute, only the
first inventor may be awarded a patent under pre-AIA 35 U.S.C. §
102(g).117 The Patent Trial and Appeal Board (“PTAB”) is the entity
that oversees the interference proceedings.118 Here, PTAB reasoned
that to declare an interference, a two way test must be used in which
“the subject matter of a claim of one party would, if prior art, have
anticipated or rendered obvious the subject matter of a claim of the

111. James W. Sanner, The Struggle for CRISPR: A Billion Dollar Question in Intellectual
Property, 2016 U. ILL. J.L. TECH. & POL'Y 431, 438 (2016).
112. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048
(P.T.A.B. 2017).
113. Sophie Lawrence et al., The competition law issues of the CRISPR patent pool, BRISTOWS
CLIPBOARD (Feb. 16, 2018), http://www.bristowsclipboard.com/post/the-competition-law-issues-ofthe-crispr-patent-pool#page=1 (“Having the Broad Institute on board is a promising start, but UC
Berkeley, holding the patent to the underlying technology, must also join for the pool to be
commercially successful.”) [https://perma.cc/Y455-A6V9].
114. See Aaron Dy, When will CRISPR get a Nobel Prize?, PUBLIC LIBRARY OF SCIENCE
(Oct.
5,
2017),
https://blogs.plos.org/synbio/2017/10/05/when-will-crispr-get-a-nobel-prize/
[https://perma.cc/46QY-WXNH];
http://kavliprize.org/prizes-and-laureates/prizes/2018-kavli-prizenanoscience [https://perma.cc/MV8P-9KDT]; Sharon Begley, Who gets credit for CRISPR? Prestigious
award singles out three, and leaves out a notable scientist, STAT (May 31, 2018),
https://www.statnews.com/2018/05/31/crispr-scientists-kavli-prize-nanoscience/
[https://perma.cc/MNA9-3758]; Kelly Servick, Broad Institute takes a hit in European CRISPR patent
struggle, SCIENCE (Jan. 18, 2018), http://www.sciencemag.org/news/2018/01/broad-institute-takes-hiteuropean-crispr-patent-struggle [https://perma.cc/G86M-9N87].
115. Id.
116. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048
(P.T.A.B. 2017).
117. Id. at 8.
118. 35 U.S.C. § 135.
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opposing party and vice versa.”119 Anticipation requires that each
element of a claim is found in a single reference.120 The University of
California admits that under this standard, none of its claims
anticipate the Broad Institute’s claims.121 Thus, PTAB reasoned that
the Broad Institute needed to show by preponderance of the evidence
that the University of California’s claims would not make the Broad
Institute’s claims obvious.122
To determine obviousness, PTAB utilized the reasonable
expectation of success standard described above.123 The Broad
Institute argued that a person having reasonable skill in the art would
not have had a reasonable expectation that the CRISPR-Cas9 system
would work successfully in a eukaryotic cell.124 The Broad Institute
used statements by the University of California inventors and their
expert witness to demonstrate that a person having ordinary skill in
the art lacked a reasonable expectation of success.125 The University
of California argues that the statements were not showing a lack of
reasonable expectation of success, but rather pointing out that
experimental results had not yet been reported.126
The Broad Institute also argued that the University of California’s
expert witness expressed many questions demonstrating lack of
reasonable expectation of success.127 The University of California
argues that statements clearly recognized the obviousness of using
the system in eukaryotic cells and expected it would be done
eventually. Their concerns were “expressing thoughts about what - if
the CRISPR-Cas system did not work in eukaryotic cells, what might
be the - the reasons.”128 PTAB agreed with the Broad Institute’s
assertion that the statements by the University of California’s
inventors and expert witnesses did not demonstrate a reasonable
expectation of success.129 The University of California pointed to the
2012 paper predicting the potential of the system for genome editing

119. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048
(P.T.A.B. 2017); see also Eli Lilly & Co. v. Bd. of Regents of Univ. of Wash., 334 F.3d 1264, 1270
(Fed. Circ. 2003).
120. Atofina v. Great Lakes Chem. Corp., 441 F.3d 991, 999 (Fed. Circ. 2006).
121. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048
(P.T.A.B. 2017).
122. Id. at 12.
123. Id.
124. Id. at 13.
125. Id. at 13-15, 16-19.
126. Id. at 16.
127. Id. at 18.
128. Id. at 19.
129. Id. at 17, 19.
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as support of its position.130 PTAB disagreed and reasoned that the
language did not indicate that the system was expected to work in
eukaryotic cells.131
The next argument put forward by the University of California was
the fact that many independent research groups simultaneously were
able to use the CRISPR-Cas9 system in eukaryotic cells after the
publication of their paper.132 PTAB did not view this as a reasonable
expectation of success, but rather evidence of motivation to do so.133
PTAB refused to accept that a scientist’s belief in success of an
experiment necessarily indicates a reasonable expectation of
success.134 PTAB further stated that if this was adopted, subject
matter would always be obvious under the KSR framework.135
PTAB relied on Pfizer Inc. v. Apotex, Inc. to state that “[u]ndue
dependence on mechanical application of a few maxims of law, such
as ‘obvious to try,’ that have no bearing on the facts certainly invites
error as decisions on obviousness must be narrowly tailored to the
facts on each individual case.”136 Pfizer was published one month
before the Supreme Court published their opinion in KSR.137
PTAB then supported its reasonable expectation of success
argument by citing to numerous cases that utilized the reasonable
expectation of success standard.138 PTAB looked to whether prior art
would instruct persons having ordinary skill in the art how to achieve
CRISPR activity in eukaryotic cells.139 PTAB also looked to prior art
that showed the success or failure of similar systems that could lead
to a reasonable expectation of success.140 The Broad Institute cited to
evidence of failed attempts of similar systems that work in vitro, but
do not work well in eukaryotic environments.141 The University of
California pointed out that this should not be indicative of a lack of
reasonable expectation of success because the similar systems were
shown to actually function in eukaryotic cells.142 The University of
130. Id. at 16.
131. Id. at 22.
132. Id. at 23.
133. Id.; see also: Abbot Labs v. Sandoz, Inc., 544 F.3d 1341, 1352 (Fed. Cir. 2008).
134. Id. at 24.
135. Id.
136. Id. at 26.
137. KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007); Pfizer, Inc. v. Apotex, Inc., 480 F.3d
1348 (Fed. Cir. 2007).
138. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048
(P.T.A.B. 2017).
139. Id. at 28.
140. Id. at 29.
141. Id. at 35-38.
142. Id. at 39.
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California also pointed to ZFNs and TALENs as similar systems that
work in eukaryotic cells.143 The Broad Institute distinguishes ZFNs
and TALENs from CRISPR by pointing out both are naturally active
in eukaryotic cells despite being prokaryotic proteins.144 Thus, the
Broad Institute would argue that the analogy put forth by the
University of California in comparing ZFNs and TALENs to
CRISPR is flawed.145
The Broad Institute distinguished another protein from CRISPR by
pointing out that CRISPR is larger in size and more complex.146
Smaller proteins are easier to introduce into a cell than larger
proteins, so the size difference is important for the likelihood of
success of introducing CRISPR into a eukaryotic cell. 147 PTAB also
decided not to consider provisional applications filed before the
Broad Institute’s patent because the evidence was not available to the
public.148 PTAB finally reasoned that the Broad Institute had shown
by preponderance of the evidence that a person having ordinary skill
in the art would not have a reasonable expectation of success.149
Thus, the Broad Institute’s patent was not invalid due to
obviousness.150
E. FEDERAL CIRCUIT’S DECISION

The Court of Appeals for the Federal Circuit heard an appeal on
the case and released their opinion on September 10, 2018.151 The
Federal Circuit reasoned that the standard of review of an
interference proceeding concerning obviousness is the same as an
obviousness review.152
The court reviewed PTAB’s ultimate conclusion of obviousness de
novo, and reviewed the underlying factual finds for substantial
supporting evidence.153 The Federal Circuit reasoned that the case
was completely dependent on the substantial evidence standard.154
143. Id. at 41.
144. Id.
145. Id.
146. Id. at 43.
147. Id.
148. Id. at 47.
149. Id. at 48-49.
150. Id.
151. Regents of the University of California v. Broad Institute, Inc., 2018 U.S. App. LEXIS
25535 (Fed. Cir. 2018).
152. Id. at 6.
153. Id. at 7.
154. Id.
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The University of California argued that PTAB “(1) improperly
adopted a rigid test for obviousness that required prior art contain
specific instructions, and (2) erred in dismissing evidence of
simultaneous invention as irrelevant.”155 Relying on the expert
testimony presented to PTAB, the Federal Circuit determined that the
substantial evidence supported PTAB’s finding that the success of
similar systems in eukaryotic cells had been unpredictable, relying on
tailoring particular conditions to the technology.156
The Federal Circuit admits that there is evidence in the record that
could have supported the University of California’s position that a
person having ordinary skill in the art would have had a reasonable
expectation of success of CRISPR-Cas9’s activity in eukaryotic
cells.157 The Federal Circuit reminded the University of California
that it is an appellate body that does not reweigh evidence.158
The Federal Circuit points out that simultaneous invention alone
cannot show obviousness, because if it did, then any claims involved
in an interference proceeding would be unpatentable for
obviousness.159 The Federal Circuit ultimately affirmed PTAB’s
judgment.160 The Federal Circuit noted the case concerned whether
the claims are patentably distinct, not whether the claims are valid.161
Ultimately, the question comes down to whether the Federal
Circuit utilized the correct analysis in the determination of
obviousness for the Broad Institute’s patent. If the reasonable
expectation of success standard was the correct analysis, then the
Federal Circuit’s ruling was correct. If more weight should have been
given to secondary factors articulated in Graham, then the Federal
Circuit’s ruling is likely incorrect. Based on Supreme Court rulings
on the obviousness standard, the more correct analysis of the two
standards is likely to rely on the secondary factors articulated in
Graham.
III. DISCUSSION

The Supreme Court and the Federal Circuit disagree over the way
to handle an issue of obviousness.162 The Supreme Court tends to
155.
156.
157.
158.
159.
160.
161.
162.
1 (1966).

Id.
Id. at 14.
Id.
Id. at 15.
Id. at 19.
Id. at 22.
Id.
See KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007); Graham v. John Deere Co., 383 U.S.
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utilize factor tests that give the court discretion based on the facts of
a particular case.163 The Federal Circuit has repeatedly tried to
develop rigid tests in an effort to make the standard more clear for
those that hold patents and those that are potentially infringing on
patents.164 This part explains why the Federal Circuit was too rigid in
its analysis of obviousness in Regents of the University of California
v. Broad Institute, Inc.,165 what facts should be considered by the
Federal Circuit, and what analysis should be used to determine
obviousness going forward.
A. The Federal Circuit’s reasonable expectation of success standard is
too rigid to test obviousness

Since the Supreme Court’s ruling in KSR v. Teleflex, the Federal
Circuit has relied on the reasonable expectation of success standard a
number of times to determine obviousness.166 Based on the frequency
and manner by which the Federal Circuit has been applying this
standard, it seems that the rule has developed into one that supplants
the Graham analysis and ignores secondary considerations.
However, in KSR v. Teleflex, the Supreme Court explicitly stated
“[b]ut a court errs where, as here, it transforms general principle into
a rigid rule limiting the obviousness inquiry.”167 The Federal Circuit
seems to have ignored this statement in their rigid application of the
reasonable expectation of success inquiry. The secondary
considerations mentioned in Graham were not applied to the facts at
hand. In Regents of the University of California v. Broad Institute,
Inc., the Federal Circuit considered the Graham factors and the
determination of a reasonable expectation of success as a question of
fact that needed substantial evidence to overturn.168 The Federal
Circuit admitted that the issue of obviousness is a question of law,169
163. See Graham v. John Deere Co., 383 U.S. 1 (1966).
164. See ACS Hosp. Sys. v. Montefiore Hosp., 732 F.2d 1572, 1577 (Fed. Cir. 1984)
(“Obviousness cannot be established by combining the teachings of the prior art to produce the claimed
invention, absent some teaching or suggestion supporting the combination.); In re Moreton, 288 F.2d
940, 944 (C.C.P.A. 1961) (The origin of reasonable expectation of success standard).
165. Regents of the University of California v. Broad Institute, Inc., 2018 U.S. App. LEXIS
25535 (Fed. Cir. 2018).
166. See Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348 (Fed. Cir. 2007); Alza Corp. v. Mylan Labs.,
Inc., 464 F.3d 1286 (Fed. Cir. 2006); In re Kubin, 561 F.3d 1351 (Fed. Cir. 2009); Takeda Chem.
Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350 (Fed. Cir. 2007); Bayer Schering Pharma A.G. v.
Barr Labs., Inc., 575 F.3d 1341 (Fed. Cir. 2009).
167. KSR Int'l Co. v. Teleflex Inc., 127 S. Ct. 1727, 1734 (2007)
168. Regents of the University of California v. Broad Institute, Inc., 2018 U.S. App. LEXIS
25535, at 6 (Fed. Cir. 2018).
169. Id.
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and erred by not considering if the Patent Trial and Appeals Board
used the correct analysis in their legal reasoning. The four Graham
factors170 should be considered, with a reasonable expectation of
success inquiry as a secondary factor to be analyzed in the context of
other facts and considerations.
B. The Federal Circuit should have considered more factors in the case

The analysis of the secondary factors articulated in Graham should
have been considered in Regents of the University of California v.
Broad Institute, Inc. The litigation at hand ultimately determines the
commercial success of each patent. Many researchers wishing to
utilize the CRISPR technologies have obtained licenses from both
groups. The Broad Institute’s attempt to create a licensing pool for
the CRISPR technology has also faced scrutiny without the addition
of the University of California’s patent.171 If anything, a
consideration of commercial success seems to help the University of
California’s position. Next, when considering long-felt need, there
was only a six-month period between the paper by the researchers
associated with the University of California172 and the second paper
by the researchers associated with the Broad Institute.173 This short
period of time does not suggest that the need was long-felt. Rather,
the short period of time between the two papers suggests the need
was relatively novel—the opposite of a long-felt need. When
considering simultaneous solution and failure of others, it should be
noted that six labs accomplished CRISPR activity in eukaryotic cells
shortly after the Broad Institute’s team accomplished the feat.174
While the Federal Circuit is correct to say some simultaneous
inventions should be expected,175 the fact that there were six
170. The prior art’s scope and content should be determined, the differences between the prior art
and the claims should be identified, and the level of ordinary skill in the art should resolved.”
Additionally, secondary considerations should be relevant as indicia of obviousness or nonobviousness..
Graham v. John Deere Co., 383 U.S. 1, 17-18 (1966).
171. Sophie Lawrence et al., The competition law issues of the CRISPR patent pool, BRISTOWS
CLIPBOARD (Feb. 16, 2018), http://www.bristowsclipboard.com/post/the-competition-law-issues-ofthe-crispr-patent-pool#page=1 (“Having the Broad Institute on board is a promising start, but UC
Berkeley, holding the patent to the underlying technology, must also join for the pool to be
commercially successful.”) [https://perma.cc/Y455-A6V9].
172. Jinek et al., A programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial
Immunity, 337 SCIENCE 816-21 (2012).
173. Cong et al., Multiplex Genome Engineering Using CRISPR/Cas Systems, 339 SCIENCE 81923 (2013).
174. Regents of the University of California v. Broad Institute, Inc., 2018 U.S. App. LEXIS
25535, at *18-19 (Fed. Cir. 2018).
175. “Inherent in the existence of interference practice is the principle that evidence of
simultaneous invention cannot alone show obviousness, otherwise any claims involved in an
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simultaneous inventions by separate labs should strengthen an
argument for the invention being obvious. Consideration of
professional approval, respect by the industry, and acclaim also helps
the argument of the University of California. Major awards in the life
sciences have favored the team from the University of California—
members of the team have won the 2014 Breakthrough Prize in Life
Sciences, 2015 Massry Prize, 2016 Canada Gairdner International
Award, 2016 Tang Prize in Biopharmaceutical Science, 2016 Warren
Alpert Foundation Prize, 2017 Albany Medical Center Prize in
Medicine and Biomedical Research,176 and 2018 Kavli Price in
Nanoscience.177 Zhang, associated with the Broad Institute, was also
named on the 2016 Canada Gairdner International Award, 2016 Tang
Prize in Biopharmaceutical Science, and the 2017 Albany Medical
Center Prize in Medicine, and Biomedical Research. However, the
only major award he received for CRISPR in the absence of members
from the University of California’s team has been the Lemelson-MIT
award (Zhang has an appointment at MIT).178 Thus far, the awards
favor the University of California due to the number and prestige of
the awards received by the University of California’s team in
comparison to the Broad Institute’s team.
However, a small number of secondary factors favor the Broad
Institute. The statements from members of the University of
California’s team leading up to the Broad Institute’s publication
could suggest unexpected results and skepticism, as PTAB and the
Federal Circuit believed. The Broad Institute’s patent also moved
through the USPTO much faster, which would strengthen the Broad
Institute’s argument. However, the Broad Institute paid the USPTO
extra fees to fast track their application.179 If foreign patent
applications are given any weight, the Broad Institute’s position
would be weakened by the European Patent Office. The European
Patent Office revoked the Broad Institute’s patent, which gives the
University of California’s team, whose patent was approved, the
interference would be unpatentable for obviousness.” Regents of the University of California v. Broad
Institute, Inc., 2018 U.S. App. LEXIS 25535, at *19 (Fed. Cir. 2018).
176. Aaron Dy, When will CRISPR get a Nobel Prize?, PUBLIC LIBRARY OF SCIENCE (Oct.
5,
2017),
https://blogs.plos.org/synbio/2017/10/05/when-will-crispr-get-a-nobel-prize/
[https://perma.cc/46QY-WXNH].
177. http://kavliprize.org/prizes-and-laureates/prizes/2018-kavli-prize-nanoscience
[http://perma.cc/MV8P-9KDT].
178. Sharon Begley, Who gets credit for CRISPR? Prestigious award singles out three, and leaves
out a notable scientist, STAT (May 31, 2018), https://www.statnews.com/2018/05/31/crispr-scientistskavli-prize-nanoscience/ [http://perma.cc/MNA9-3758].
179. Jon Cohen, How the battle lines over CRISPR were drawn, SCIENCE (Feb. 15, 2017),
https://www.sciencemag.org/news/2017/02/how-battle-lines-over-crispr-were-drawn
[http://perma.cc/396J-ZBHM].
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dominant position in the European market.180
C. Incorporating the Reasonable Expectation of Success and Obviousto-Try Standards with the Graham Factors

Almost all cases in patent law that deal with a question of
obviousness are very context specific. In situations like this, rigid
rules handed down by the court are not the ideal method for
distributing justice. Rather, the court should use flexible tests with
factors, such as the Graham secondary considerations, to apply the
facts of a case and use reasonable discretion to determine what the
outcome should be.
The obvious-to-try and reasonable expectation of success
standards should be treated as secondary factors in a Graham inquiry.
They could be viewed as they are now, or they could be viewed in
light of other secondary factors. In scenarios motivated by an
exceptionally large economic incentive, an experiment may be
obvious to try because the risk is worth the reward. Similarly, the
reasonable expectation of success could depend on the economic
incentive in the event of success. When an industry changing patent
that is extremely valuable is on the other end of the tunnel, then the
probability of success needed for the expectation of success to be
reasonable may be fairly low. If the patent is not particularly
valuable, then that probability of success should be higher in order
for the expectation of success to be reasonable. In other words,
reasonable expectation of success should be interpreted more as a
reasonable probability of success.
Applying this standard to the CRISPR dispute, it was foreseeable
that CRISPR would change billion-dollar industries, thus the
reasonable likelihood of success to suggest to a person having
ordinary skill in the art to try should not be very high. The rewards
from a tool of this scale would outweigh the risk despite low odds.
As a policy matter, the purpose of the patent system is to grant an
exclusive monopoly to a patentee in exchange for their timely
disclosure of their invention so that said invention could be used for
public good once the patent expires. Here, the team from the
University of California filed first and their claims would seem to
make the Broad Institute’s claims obvious. Future inventors in the
genome editing sciences could look to this case and decide not to
disclose their invention until there has been proof of concept in
180. Kelly Servick, Broad Institute takes a hit in European CRISPR patent struggle, SCIENCE
(Jan. 18, 2018), http://www.sciencemag.org/news/2018/01/broad-institute-takes-hit-european-crisprpatent-struggle [http://perma.cc/G86M-9N87].
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eukaryotes. This could harm the progress of the sciences, which is in
direct opposition to the stated purpose of the United States
Constitution in permitting Congress to grant patents.181
IV. CONCLUSION

In its most recent decision dealing with the obviousness standard,
the Supreme Court warned against using too rigid of a test to
determine whether an invention was obvious in light of the prior art.
Indeed, the standard used by the Supreme Court has been a factor
analysis, which gives the lower courts plenty of flexibility to rule on
a case. Patent law in particular is a field of law in which disputes are
context specific. Thus, the flexible secondary factor analysis used by
the Supreme Court is superior to the rigid reasonable expectation of
success standard utilized by the Federal Circuit.
Here, the team from the University of California were the first to
patent the CRISPR invention in an unrestricted system. Multiple labs
made the CRISPR system work in eukaryotes shortly after the Broad
Institute. The University’s researchers posited the idea of using
CRISPR in eukaryotes in their publication. The economic incentive is
so large that the likelihood of success does not need to be very high
in order for it to be reasonable to try. The next step in the University
of California’s invention was to make it work in eukaryotes with
standard practices, thus the Broad Institute’s patent was obvious to
try. Other scientists in the biological sciences seem to be awarding
the University of California’s researchers more than the Broad
Institute’s researchers. A real possibility exists that the University of
California’s team will win the Nobel Prize. There seems to be a
disconnect between the law and the scientific community that may
result in an absurd scenario in which the University of California’s
team could win the Nobel Prize for CRISPR without holding the
most valuable patent for CRISPR, which belongs to the Broad
Institute.

181. U.S. CONST. art. I, § 8, cl. 8 grants Congress the power to “promote the Progress of Science
and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their
respective Writings and Discoveries.”
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